Neurocrine Likely To Seek Women’s Health Partner For Endometriosis Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurocrine expects to carry development of its gonadotrophin-releasing hormone receptor antagonist through Phase IIb before partnering.
You may also be interested in...
Indiplon Driving Study Could Push Marketing Into High Gear
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.